Skip to content
Sample Page
Author:
Scynexis
Posted Date:
June 30, 2026
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Scynexis
June 30, 2026
SCYNEXIS Announces One-for-Eight Reverse Stock Split
Scynexis
May 22, 2026
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Scynexis
May 11, 2026
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Scynexis
May 6, 2026
SCYNEXIS Announces $40.0 Million Private Placement
Scynexis
March 31, 2026
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Scynexis
March 31, 2026
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Scynexis
March 5, 2026
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Scynexis
January 28, 2026
